These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 6323321)

  • 21. In vitro activity against clinically important gram-positive and gram-negative bacteria of sulbactam, alone and in combination with ampicillin, cefotaxime, mezlocillin, and piperacillin.
    Schmalreck AF; Wildfeuer A
    Arzneimittelforschung; 1990 Oct; 40(10):1145-55. PubMed ID: 2291754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro efficacy of sulbactam combined with ampicillin against anaerobic bacteria.
    Wexler HM; Harris B; Carter WT; Finegold SM
    Antimicrob Agents Chemother; 1985 May; 27(5):876-8. PubMed ID: 2990330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
    Nomura S; Hanaki H; Nagayama A
    J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effects of ampicillin and cefazolin combined with mecillinam (author's transl)].
    Stille W; Bischof-Léger E; Helm EB
    Arzneimittelforschung; 1978; 28(10):1661-4. PubMed ID: 226099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacodynamics of ampicillin-sulbactam in an in vitro infection model against Escherichia coli strains with various levels of resistance.
    Lamp KC; Vickers MK
    Antimicrob Agents Chemother; 1998 Feb; 42(2):231-5. PubMed ID: 9527765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of inoculum size on the activity of cefoperazone-sulbactam against multidrug resistant organisms.
    Chang PC; Chen CC; Lu YC; Lai CC; Huang HL; Chuang YC; Tang HJ
    J Microbiol Immunol Infect; 2018 Apr; 51(2):207-213. PubMed ID: 29037802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bacteriological studies with ampicillin/sulbactam on selected strains of gram-negative bacteria.
    Bello H; del Solar E; González C; Garcia A; Urrea R; Zemelman R
    Diagn Microbiol Infect Dis; 1988 Oct; 11(2):109-15. PubMed ID: 3067960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time-kill kinetic studies of ampicillin/sulbactam for beta-lactamase-producing enterococci.
    Patterson JE; Farrel P; Zervos MJ
    Diagn Microbiol Infect Dis; 1991; 14(6):495-9. PubMed ID: 1802536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergy of sulbactam and ampicillin against methicillin-resistant staphylococci.
    Chin NX; Neu NM; Neu HC
    Drugs Exp Clin Res; 1986; 12(12):939-42. PubMed ID: 3032552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular genetics of resistance to both ceftazidime and beta-lactam-beta-lactamase inhibitor combinations in Klebsiella pneumoniae and in vivo response to beta-lactam therapy.
    Rice LB; Carias LL; Bonomo RA; Shlaes DM
    J Infect Dis; 1996 Jan; 173(1):151-8. PubMed ID: 8537652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.
    Bonomo RA; Rudin SA; Shlaes DM
    FEMS Microbiol Lett; 1997 Mar; 148(1):59-62. PubMed ID: 9066111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of bacterial strains producing sulbactam- or tazobactam-sensitive beta-lactamases by the use of disks containing the inhibitors alone instead of combining them with antibiotics.
    Banic S
    APMIS; 2006 Jan; 114(1):3-9. PubMed ID: 16499654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Synergistic effect of ampicillin and dicloxacillin on penicillin and cephalosporin-susceptible Escherichia coli (author's transl)].
    Morohoshi T; Sagai H; Mizoguchi J; Otani M
    Jpn J Antibiot; 1978 Oct; 31(10):606-9. PubMed ID: 366193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro susceptibilities of Escherichia coli and Klebsiella spp. to ampicillin-sulbactam and amoxicillin-clavulanic acid.
    Kacmaz B; Sultan N
    Jpn J Infect Dis; 2007 Jul; 60(4):227-9. PubMed ID: 17642541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Susceptibility of Haemophilus ducreyi to ampicillin and sulbactam in vitro.
    Jones BM; Hafiz S; Duerden BI
    Antimicrob Agents Chemother; 1986 Jun; 29(6):1110-2. PubMed ID: 3015016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Analysis of antibiotic resistance and genotypes on extended spectrum β-lactamase and AmpC β-lactamase producing strains isolated from Uygur and Han newborns].
    Zhang WL; Liu J; Zhang J; Su GL
    Zhonghua Yu Fang Yi Xue Za Zhi; 2011 Mar; 45(3):217-24. PubMed ID: 21624232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Synergy between sulbactam and ampicillin or cefoperazone in antimicrobial activity against beta-lactamase producing microorganisms. Results with the use of microdilution broth method].
    Deguchi K; Yokota N; Koguchi M; Nakane Y; Fukushima Y; Fukayama S; Ishihara R; Oda S; Tanaka S; Sato K
    Jpn J Antibiot; 1990 Jul; 43(7):1214-24. PubMed ID: 2232151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae.
    Titelman E; Karlsson IM; Ge Y; Giske CG
    Diagn Microbiol Infect Dis; 2011 May; 70(1):137-41. PubMed ID: 21513849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Escherichia coli resistant to ampicillin/sulbactam.
    Eng RH; Yen K; Smith SM; Citron DM; Goldstein EJ; Greenberg R; Cherubin CE
    Chemotherapy; 1992; 38(6):399-404. PubMed ID: 1288964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.